Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe

Janssen‐Heijnen, M.L.G.; Coebergh, Jan Willem

doi:10.1016/s0169-5002(00)00197-5

Cited by 174 publications

(133 citation statements)

References 147 publications

(169 reference statements)

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…In our study, among the biomarkers tested, only aurora B could predict prognosis, limited to the adenocarcinoma patients. This histologic subtype is on the increase and represents nowadays the most frequent subtype in North America and Northern Europe (42). Although it needs further validation, our finding might be important for the clinical management of these patients.…”

Section: Discussionmentioning

confidence: 53%

Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients

Vischioni

Oudejans²,

Vos³

et al. 2006

Molecular Cancer Therapeutics

119

View full text Add to dashboard Cite

The serine/threonine protein kinase aurora B, a key regulator of mitosis, is emerging as a novel drug target for cancer treatment. Aurora B overexpression has been previously documented by immunohistochemistry in several types of human tumors. We assessed aurora B expression in a series of 160 non -small cell lung cancer (NSCLC) samples (60% stage I, 21% stage II, 11% stage III, and 8% stage IV). In addition, we determined the expression of survivin and p16, two molecules also involved in cell cycle control. Aurora B was expressed selectively in tumor cells compared with normal epithelium. Aurora B expression was significantly correlated with expression of survivin in the nucleus (P < 0.0001), but not with expression of p16 (P = 0.134). High aurora B expression levels were significantly associated with older age (P = 0.012), male sex (P = 0.013), squamous cell carcinoma histology (P = 0.001), poor tumor differentiation grade (P = 0.007), and lymph node invasion (P = 0.037), in the subset of radically resected patients in our series. In addition, aurora B expression predicted shorter survival for the patients with adenocarcinoma histology, at both univariate (P = 0.020) and multivariate (P = 0.012) analysis. Survivin expression levels were neither associated with patient clinicopathologic characteristics nor with survival. However, expression of survivin in the nucleus was preferentially detected in stage I and II than in stage III and IV (P = 0.007) in the overall series of NSCLC samples. Taken together, our results suggest that aurora B may represent a valid target in NSCLC. [Mol Cancer Ther 2006;5(11):2905 -13]

show abstract

Section: Discussionmentioning

confidence: 53%

Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients

Vischioni

Oudejans²,

Vos³

et al. 2006

Molecular Cancer Therapeutics

119

View full text Add to dashboard Cite

show abstract

“…3 Among the four major histological types of lung cancer, adenocarcinoma has been rising in incidence in recent years 4 and is a focus of intense investigations. The discovery of the mutation of the epidermal growth factor receptor (EGFR) gene has been a major breakthrough in lung cancer.…”

Section: Japanmentioning

confidence: 99%

Co-Activation of Epidermal Growth Factor Receptor and c-MET Defines a Distinct Subset of Lung Adenocarcinomas

Matsubara

Ishikawa

Oguni

et al. 2010

The American Journal of Pathology

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) and MET are molecular targets for lung cancer treatment. The relationships between expression, activation, and gene abnormalities of these two targets are currently unclear. Here, we demonstrate that a panel of 40 lung cancer cell lines could be classified into two groups. Group I was characterized by (1) high phosphorylations of MET and EGFR, (2) frequent mutation or amplification of EGFR, MET, and human epidermal growth factor receptor-2 (HER2), (3) high expressions of bronchial epithelial markers (thyroid transcription factor-1 (TTF-1), MUC1, and Cytokeratin 7 (CK7)); and (4) high expressions of MET, human epidermal growth factor receptor-3, E-cadherin, cyclooxygenase-2, and laminin gamma2. In contrast, Group II exhibited little or no phosphorylation of MET and EGFR; no mutation or amplification of EGFR, MET, and HER2; were triple-negative for TTF-1, MUC1, and CK7; and showed high expressions of vimentin, fibroblast growth factor receptor-1, and transcription factor 8. Importantly, Group I was more sensitive to gefitinib and more resistant to cisplatin and paclitaxel than Group II. The clinical relevance was confirmed in publicly available data on 442 primary lung adenocarcinoma patients; survival benefits by postoperative chemotherapy were seen in only patients with tumors corresponding to Group II. Overall, co-activation of EGFR and MET defines a distinct subgroup of lung carcinoma with characteristic genetic abnormalities, gene expression pattern , and response to chemotherapeutic reagents. (Am J

show abstract

“…1 Moreover, the incidence of lung adenocarcinoma is widely recognized to be increasing among industrialized countries. 2 The prognosis of lung carcinoma is poor: even if diagnosed successfully, patients with stage I lung carcinoma have a 5-year survival rate of only 70% after surgical resection. 3 In 1995, Noguchi et al 4 proposed a new histological classification for lung adenocarcinomas of small size (maximum dimension 2 cm or less).…”

mentioning

confidence: 99%

Subepithelial myofibroblast in lung adenocarcinoma: a histological indicator of excellent prognosis

et al. 2009

View full text Add to dashboard Cite

We report here the presence of subepithelial myofibroblasts in pure bronchioloalveolar carcinoma and a subset of invasive lung adenocarcinoma. The subepithelial myofibroblasts we describe were observed in a peculiar location beneath the cancer cells in the alveolar septa. Immunohistochemically, they were positive for a-smooth muscle actin and calponin, but negative for desmin and h-caldesmon. To gain insight into their biological significance, we examined 116 surgically resected lung adenocarcinomas. The resected tumors included 13 bronchioloalveolar carcinomas, 20 mixed type adenocarcinomas with bronchioloalveolar carcinoma components, 57 papillary adenocarcinomas, 22 solid adenocarcinomas with mucin, and 4 acinar adenocarcinomas. All specimens were immunostained for a-smooth muscle actin to visualize the myofibroblasts. In all of the pure bronchioloalveolar carcinomas observed, the subepithelial myofibroblasts were completely preserved adjacent to the cancer cells. In mixed adenocarcinomas with bronchioloalveolar carcinoma components, subepithelial myofibroblasts were present in the bronchioloalveolar carcinoma components, but scanty in the invasive areas, where stromal myofibroblasts emerged between the cancer cell nests. Subepithelial myofibroblasts were retained, however, in the invasive areas of a subset of invasive adenocarcinomas. Survival analysis showed that the retention of subepithelial myofibroblasts in these invasive tumors was associated with low rates of lymphatic and vascular invasion, a low rate of lymph node involvement, and an excellent patient survival. These results suggest that subepithelial myofibroblasts increase in bronchioloalveolar carcinomas, but are gradually replaced by typical stromal myofibroblasts during progression into invasive cancer. A subset of invasive adenocarcinomas retains subepithelial myofibroblasts. Analysis of subepithelial myofibroblasts may be helpful in identifying a subset of lung adenocarcinoma with excellent prognosis.

show abstract

Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe

Abstract: The epidemic of lung cancer is not over yet, especially in southern and eastern Europe. Except for short-term survival of small cell tumours, the prognosis for patients with lung cancer has not improved significantly.

Cited by 174 publications

References 147 publications

Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients

Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients

Co-Activation of Epidermal Growth Factor Receptor and c-MET Defines a Distinct Subset of Lung Adenocarcinomas

Subepithelial myofibroblast in lung adenocarcinoma: a histological indicator of excellent prognosis

Contact Info

Product

Resources

About